NCT06412172 The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
| NCT ID | NCT06412172 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Recurrent Respiratory Papillomatosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-04-15 |
| Primary Completion | 2026-04-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-04-15 with a primary completion date of 2026-04-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Recurrent respiratory papillomatosis (RRP) is an orphan disease that affects approximately 20,000 people in the United States and is caused by infection with human papillomavirus (HPV) types 6 and 11. Since RRP is an orphan disease, it is an understudied disease entity with correspondingly few treatment options. The investigators hypothesize that by understanding the biology of RRP and the failed host immune responses against HPV, novel and rational therapies can be developed. This study will examine the genetic and immunologic alterations found in these rare tumors and distant metastatic involved sites (such as the lung) in patients diagnosed with RRP.
Eligibility Criteria
Inclusion Criteria: * History of HPV-associated Recurrent Respiratory Papillomatosis * Has pulmonary lesions Exclusion Criteria: * None
Contact & Investigator
Sara Pai
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT06412172 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Recurrent Respiratory Papillomatosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06412172 currently recruiting?
Yes, NCT06412172 is actively recruiting participants. Contact the research team at RRPBiorepository@yale.edu for enrollment information.
Where is the NCT06412172 trial being conducted?
This trial is being conducted at New Haven, United States.
Who is sponsoring the NCT06412172 clinical trial?
NCT06412172 is sponsored by Massachusetts General Hospital. The principal investigator is Sara Pai at Yale University. The trial plans to enroll 100 participants.